[Efficacy and safety of enoxaparin use during drug-eluting stents implantation]
| Autor: | Mustafaoglu F, Ln, Petrakova, Igor Pershukov, Ta, Batyraliev, Pia IuV, Ia, Lazarev, Dm, Ramazanov, Lv, Shul Zhenko, Bk, Kadyrov, Dv, Sal Nikov, Nn, Dolgikh, Ba, Sidorenko |
|---|---|
| Rok vydání: | 2008 |
| Předmět: |
Adult
Aged 80 and over Male Middle Aged Coronary Angiography Prosthesis Design Blood Vessel Prosthesis Implantation Electrocardiography Treatment Outcome Coated Materials Biocompatible Fibrinolytic Agents Humans Female Stents Angina Unstable Coronary Artery Bypass Enoxaparin Aged Follow-Up Studies Retrospective Studies |
| Zdroj: | Europe PubMed Central |
| ISSN: | 0022-9040 |
| Popis: | We assessed possibility of the use of low molecular heparin enoxaparin during percutaneous coronary interventions (PCI) with implantation of drug eluting stents. Enoxaparin was administered to 225 (0.3 mg/kg intraarterially via catheter) and 215 (0.5 mg/kg intravenously) patients. In comparison group (n=207) we used unfractionated heparin (UFG) intravenously according to standard scheme under control of activated clotting time. Stents implanted (n=797) were Cypher, Taxus, and Endeavor. Immediate angiographic success was 100%. During 48 hours after PCI pronounced bleeding (4.3%) and blood transfusions predominated in UFG treated patients. Number of bleedings was minimal after the intra-arterial use of enoxaparin (0.3 mg/kg). However total rate of all adverse events after PCI turned out to be minimal (7.0%) in the group of patients receiving enoxaparin intravenously (0.5 mg/kg). Thus the use of low molecular heparin enoxaparin is justified during implantation of drug eluting stents. Its optimal dose according to data obtained is 0.5 mg/kg intravenously. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|